Xilio Therapeutics Files 8-K
Ticker: XLO · Form: 8-K · Filed: Nov 7, 2025 · CIK: 1840233
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Xilio Therapeutics filed a standard 8-K on 11/7/2025. No major news.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on November 7, 2025, reporting on Item 8.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing indicates routine corporate reporting by Xilio Therapeutics, Inc. to the SEC, without disclosing specific material events or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would impact risk.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- November 7, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 001-40925 (commission_file_number) — SEC File Number
- 85-1623397 (ein) — IRS Employer Identification No.
- 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (address) — Principal Executive Offices
- (857) 524-2466 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Item 8.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits) as of November 7, 2025.
What is the exact name of the reporting company?
The exact name of the reporting company is Xilio Therapeutics, Inc.
On what date was this report filed?
This report was filed on November 7, 2025.
In which state was Xilio Therapeutics, Inc. incorporated?
Xilio Therapeutics, Inc. was incorporated in Delaware.
What are the principal executive offices of Xilio Therapeutics, Inc.?
The principal executive offices of Xilio Therapeutics, Inc. are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-07 09:05:24
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share XLO Nasdaq Capital Market
Filing Documents
- xlo-20251107.htm (8-K) — 62KB
- xlo-ex99_1.htm (EX-99.1) — 43KB
- xlo-ex99_2.htm (EX-99.2) — 59KB
- 0001193125-25-271189.txt ( ) — 298KB
- xlo-20251107.xsd (EX-101.SCH) — 31KB
- xlo-20251107_htm.xml (XML) — 5KB
01. Other Events
Item 7.01. Other Events. On November 7, 2025, Xilio Therapeutics, Inc. (the "Company") issued a press release announcing new data related to high plasma tumor mutational burden from its ongoing Phase 2 clinical trial evaluating vilastobart in combination with atezolizumab in patients with microsatellite stable metastatic colorectal cancer, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also on November 7, 2025, the Company issued a press release announcing updated data across its portfolio, including preclinical data for the Company's masked T cell engager platform and programs, as well as updated Phase 1 data for efarindodekin alfa, and Phase 2 data related to circulating tumor DNA for vilastobart, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K. These data are presented in poster presentations at the Society for Immunotherapy of Cancer (SITC) 40 th Annual Meeting. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release issued by Xilio Therapeutics, Inc. on November 7, 2025 99.2 Press release issued by Xilio Therapeutics, Inc. on November 7, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: November 7, 2025 By: /s/ Caroline Hensley Caroline Hensley Chief Legal Officer